Conference Coverage

Chlamydia infections associated with more than a doubling of ovarian cancer risk


 

FROM THE AACR ANNUAL MEETING

Pelvic inflammatory disease caused by chlamydia appears to significantly increase the risk of ovarian cancer, according to research to be presented at the annual meeting of the American Association for Cancer Research.

The finding, replicated in two large databases, suggests that promptly treating the infection might reduce the lifetime risk of developing ovarian cancer, Britton Trabert, PhD, said during a press briefing held in advance of the meeting.

Dr. Britton Trabert, National Cancer Institute, Bethesda, Md.

Dr. Britton Trabert

“Although these findings need to be replicated, they suggest potential ovarian cancer risk reduction through targeted treatment of chlamydia infections,” said Dr. Trabert, the Earl Stadtman Investigator at the National Cancer Institute.

The study portends both promise and challenge, according to Elaine R. Mardis, PhD, who comoderated the session.

Pages

Recommended Reading

FDA: Laparoscopic power morcellators can spread malignant cells when used in women with occult uterine cancers*
MDedge Hematology and Oncology
Age at RRSO affects peritoneal cancer risk in BRCA mutation carriers
MDedge Hematology and Oncology
HIPEC shows survival benefit for advanced ovarian cancer
MDedge Hematology and Oncology
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Hematology and Oncology
Experimental PD-1/PARP inhibitor combo shows promise in solid tumors
MDedge Hematology and Oncology
Pembrolizumab plus SBRT shows promise for advanced solid tumors
MDedge Hematology and Oncology
Letrozole promising as maintenance treatment for high-grade serous ovarian cancer
MDedge Hematology and Oncology
USPSTF: Routine screens for ovarian cancer not recommended
MDedge Hematology and Oncology
Avelumab safety compares with other checkpoint inhibitors
MDedge Hematology and Oncology
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Hematology and Oncology